Benzodiazepine Hypnotic — Long-acting
Pregnancy: Avoid — neonatal respiratory depression, hypotonia, and withdrawal. Long half-life means neonatal effects may persist for days after delivery.
Nitrazepam
Brand names: Mogadon
Adult dose
Dose: Insomnia (short-term): 5mg at bedtime; elderly: 2.5mg at bedtime. Maximum treatment duration: 2–4 weeks.
Route: Oral
Frequency: Once nightly at bedtime
Max: 10mg OD (non-elderly adults — rarely required); 5mg OD (elderly)
Long-acting benzodiazepine hypnotic (half-life 16–38h) — significant next-day 'hangover' sedation and psychomotor impairment. Generally less preferred than temazepam (shorter-acting) due to greater residual sedation, falls risk in elderly, and cognitive impairment. Reserve for when shorter-acting hypnotics have failed. CD prescription not required (unlike temazepam) — schedulehas varied over time; check current legal status.
Paediatric dose
Route: Oral
Frequency: Once nightly
Max: Not applicable
Not licensed for insomnia in children. Used under specialist supervision in paediatric epilepsy (myoclonic, infantile spasms — see BNFc). Seek specialist paediatric neurology opinion for epilepsy use.
Dose adjustments
Renal
Use with caution in renal impairment — enhanced sedation and accumulation risk; reduce dose.
Hepatic
Avoid in severe hepatic impairment — accumulation risk; hepatic metabolism.
Clinical pearls
- Antidote: flumazenil 200 micrograms IV, then 100 micrograms every 60 seconds (max 1mg) — note: nitrazepam half-life (16–38h) exceeds flumazenil half-life; repeat doses or infusion may be required
- Falls risk in elderly: avoid nitrazepam in elderly — Beers Criteria and STOPP criteria explicitly list long-acting benzodiazepines as potentially inappropriate in older adults due to falls, cognitive impairment, and fractures
- Hangover sedation: next-day impairment is significant — advise patients not to drive or operate machinery the morning after taking nitrazepam (impairment may persist 12–18h)
- NICE NG215: temazepam preferred over nitrazepam for insomnia when benzodiazepine is needed — shorter half-life means less next-day impairment
Contraindications
- Respiratory failure
- Myasthenia gravis
- Sleep apnoea syndrome
- Severe hepatic impairment
- Acute angle-closure glaucoma
- Hypersensitivity to benzodiazepines
Side effects
- Residual morning sedation (very common — long half-life)
- Cognitive impairment, memory disturbance
- Ataxia, falls (particularly in elderly)
- Paradoxical agitation
- Dependence and withdrawal
- Respiratory depression (at higher doses or with CNS depressants)
- Anterograde amnesia
Interactions
- CNS depressants, opioids, alcohol — additive respiratory depression and sedation
- CYP3A4 inhibitors — may increase nitrazepam levels
- Rifampicin — reduces nitrazepam efficacy
Monitoring
- Duration of use (strict 2–4 week limit)
- Next-day sedation and driving safety
- Falls assessment in elderly
- Dependence symptoms
Reference: BNFc; BNF 90; NICE NG215 (Insomnia); Beers Criteria; STOPP/START Criteria. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Corrected QT Interval (Bazett) · ECG
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Benzodiazepine Conversion Calculator · Drug Conversion
- Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal · Critical Care
- CIWA-Ar — Alcohol Withdrawal Scale · Diagnosis
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF